Comments
Natco Pharma has posted a profit of ₹299.7 core for the fourth quarter ended March 31, 2018, against a profit of ₹176.4 crore, up 69.9 per cent for the corresponding quarter in the previous fiscal on a consolidated basis.
The Hyderabad-based pharma company registered total income of ₹787.9 crore, up 32.9 per cent (₹ 577.2 crore).
It registered a profit of ₹695 crore and revenue of ₹2,242 crore for the financial year ended March 31, 2018, against a profit of ₹484.9 crore and revenue of ₹2078.9 crore for the previous financial year.
The growth in revenue and profit during the year was driven primarily by formulations business in the US that included niche generic product launches of Glatiramer Acetate, Liposomal Doxorubicin and Lanthanum Carbonate.
Additionally, generic Oseltamivir sales in the US was a strong contributor for the company in spite of competition, the company, VC Nannapaneni, Chairman and Managing Director, said in a statement.
The domestic oncology formulations business continued to be strong during the year.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.